UNSPSC 51313428: Dexchlorpheniramine maleate

This classification denotes a histamine-1 receptor antagonist with the molecular formula C16H19ClN2.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B10YD955QW, chemically known as 3-(p-chlorophenyl)-3-(2-pyridyl)-n,n-dimethylpropylamine but more generally known as dexchlorpheniramine maleate, which bears US NIH Compound Identifier 2725. European Medicines Agency schedules Dexchlorpheniramine maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01628MIG.

UNSPSC 51313428 Dexchlorpheniramine maleate is a Commodity code that frames the procurement of specific pharmaceutical active ingredients and finished medications rather than the abstract chemical name alone. State and local governments use this code to buy individual drugs and pharmaceutical products for health departments, public health programs, emergency response systems, and community health facilities. The issuing bodies include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances that aggregate demand across multiple jurisdictions. Recent activity shows county and state procurement offices soliciting naloxone, safe drug deactivation systems, and generic multi-source pharmaceuticals through competitive bidding processes, with vendors required to comply with FDA manufacturing standards, Drug Supply Chain Security Act requirements, and E-Verify employment verification.

Recent opportunities span Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building; the response deadline was July 26, 2023. The Texas Health and Human Services Commission released RFI HHS0017013 on April 3, 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, seeking information about vendors' capacity to contract directly with self-insured health plans and state agencies outside traditional pharmacy benefit manager and wholesaler arrangements. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance, issued RFP S1070000015802 on January 20, 2026 with a March 26, 2026 response deadline to establish contracts for generic multi-source pharmaceuticals and OTC products; proposals require detailed product information including National Drug Codes, pricing submission in multiple formats, maintenance of relationships with at least two of three authorized wholesalers, and compliance with cGMP and DSCSA standards. Contract terms typically span two years with optional renewals, and vendors must carry commercial general liability insurance of $5,000,000 per occurrence and professional liability of $2,000,000.